Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.READ MORE
Significant Hb changes
can
happen over time
of patients had a mean monthly Hb change that caused them to move out of the ≥ 10 to ≤ 11 g/dL range from baseline by month 81,*
of patients experienced an unpredictable clinical event2.†
*These patients had a mean baseline Hb ≥ 10 to ≤ 11 g/dL when monitoring began.
Data are from OutcomesPlus, a national database of clinical data from patients receiving dialysis in facilities across the United States, excluding hospital and governmental entity patients. It contains information from the majority of the US dialysis population. The analyses consisted of calculating the monthly Hb levels, monthly Hb categories, and the change in Hb categories for individual patients from April 2013 to December 2013 (N = 1674). Patients were included if both intravenous ESA dose and Hb data were available for every month of the time period. Each patient's initial Hb category, during the baseline month, was used as the reference over time. Patients were categorized within a "moved to" group once they moved out of their baseline month category, and they were counted within a "remained" category if they maintained the same Hb category as the baseline month (until the month of the first change).
†Based on a 6-month, retrospective analysis of all Medicare primary payer hemodialysis patients who survived and had ESA claims in the first 6 months of 2004 (N = 159,720). Unpredictable clinical events patients experienced during the 6-month study included hospitalization, vascular access insertions/complications, or receipt of IV antibiotics (ie, more serious infections).
UNPREDICTABLE CLINICAL EVENTS CAN INCLUDE:
Address Hb excursions by intervening
with Aranesp®
Aranesp® dosing intervals provide an ability to intervene, helping to:
of Hb monitoring practices occur within 2 weeks, which is similar to Aranesp® dosing intervals7,9,‡
‡Data are from OutcomesPlus, a national database of clinical data from patients receiving dialysis in facilities across the United States, excluding hospital and governmental entity patients. It contains information from the majority of the US dialysis population. The analysis consisted of calculating an average quarterly frequency of Hb monitoring from Q1 2014 to Q2 2017 from MDOs.
MDO = medium dialysis organization.
1
Monitor Hb regularly§ and note the trend of a patient’s Hb values over time to more accurately assess Hb status7
§At least weekly until stable and then at least monthly.
2
Once the patient’s data have been trended, the future Hb response may be predicted by evaluating the rate at which Hb is decreasing or increasing7
3
Based on the prediction, clinicians can intervene to address underlying conditions that may affect the patient’s Hb level and determine whether an adjustment of the Aranesp® dose is needed7
WATCH a hypothetical patient case study on the experience of a patient with anemia due to CKD. Stream video now at anemiahub.com
§At least weekly until stable and then at least monthly.
i
**Please see Aranesp® Dosing Information.
The molecular structure of Aranesp® provides extended erythropoietic activity11,12
MOA = mechanism of action.
i
Due to the extended erythropoietic activity of Aranesp®,
it can be dosed once weekly or once every 2 weeks7,11,12
Important Safety Information including Boxed WARNINGS
Important Safety Information including Boxed WARNINGS
